Target discovery is one of our core skills, allowing the selection of suitable target molecules for cancer and other diseases. Diverse influences may drive such target structures to be unusually activated or mutated, or bring about a gene fusion encoding a new target. Such targets may accumulate in certain tumor types, or in individual patients.
In Vivo Imaging
Imaging techniques are crucial for observing and monitoring physiological or environmental changes at organ, tissue, cell, and molecular level. Non-invasive imaging modalities are particularly important for longitudinal animal studies. The In Vivo Imaging facility of the Immunotherapy Development Center (IDC) provides imaging services and consultation on the planning, execution and analysis of fluorescence and bioluminescence experiments
The use of (auto)antibodies as markers is one of the most promising prognostic and diagnostic approaches to classify disease and requires minimal invasive intervention. (Auto)antibodies are excellent biomarkers because they are robust, naturally amplified by the immune system, immunologically memorized and readily detectable. The TRON Biomarker Development Center (BDC)’s Serodiscovery Core Facility provides in-house research
The TRON Vectors Unit is part of the Immunotherapy Development Center (IDC) and provides state-of-the-art gene transfer technologies to other units and teams of TRON. A key focus is on retroviral gene transfer. However we also expand our spectrum of methods on an ongoing basis by establishing aditional gene transfer techniques, such as transposons and alphaviral
Applied Bioinformatics is one of the key life sciences’ disciplines of the 21st century. State-of-the-art bioinformatic approaches are proving indispensable in the development of highly innovative and individual therapies, which focus on the disease-specific molecular changes of each individual patient. TRON’s Bioinformatics department comprises the following groups: Computational Medicine, Data Management and Personalized Integrative Computational
Every cell in the human body contains that person’s entire genome. This also applies to a tumor cell, except that certain influences drive the occurrence of small or large variations in the genome. Identifying the unique changes in each patient may help determine the underlying cause of disease and support the development of individualized therapy
TRON provides expert research and specialized high-end technologies to biotechnology companies and research groups. The organization was specifically designed to advance the field of individualized medicine. TRON has two major research departments: The Biomarker Development Center (BDC), headed by Dr. Andrée Rothermel and Dr. Valesca Bukur, researches and validates clinically relevant molecular, cellular, and serological